Adam Hirst completed his PhD in Stem Cell Biology from the University of Sheffield where his research focused on genomic instability in human pluripotent stem cells. He then worked as a Research Fellow at the University of Nottingham studying the specification of primordial germ cells in non-rodent mammals. Adam is currently a Scientist at STEMCELL Technologies, developing products to facilitate innovative techniques such as gene-editing in human pluripotent stem cells.
Andrew Gaffney completed his PhD in Pediatric Oncology from the University of Leeds, UK, where he successfully established a human embryonic stem cell disease model of Ewing sarcoma. He joined STEMCELL Technologies in 2014 as a Global Technical Specialist where he provided advanced customer support in the areas of human pluripotent stem cell (hPSC) maintenance and differentiation. Since 2016, Andrew has been working as the Product Manager for STEMCELL's PSC portfolio of products. He works closely with renowned stem cell scientists in both industry and academia to monitor the requirements needed for establishing successful hPSC-based disease models, drug screens and cell therapy applications.
Tuesday February 27, 2018 - 10am PST | 1pm EST | 6pm UTC
If you are unable to attend the live webinar, please register and we will send you a link to view the recording when it becomes available.